AstraZeneca
AZN
1,091 hedge funds and large institutions have $35.3B invested in AstraZeneca in 2023 Q2 according to their latest regulatory filings, with 112 funds opening new positions, 337 increasing their positions, 386 reducing their positions, and 67 closing their positions.
67% more first-time investments, than exits
New positions opened: 112 | Existing positions closed: 67
15% more funds holding in top 10
Funds holding in top 10: 13 → 15 (+2)
3% more funds holding
Funds holding: 1,055 → 1,091 (+36)
1% more capital invested
Capital invested by funds: $35B → $35.3B (+$335M)
0.46% less ownership
Funds ownership: 16.39% → 15.92% (-0.46%)
13% less repeat investments, than reductions
Existing positions increased: 337 | Existing positions reduced: 386
21% less call options, than puts
Call options by funds: $641M | Put options by funds: $815M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$413M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$125M |
| 3 |
Goldman Sachs
New York
|
+$96.6M |
| 4 |
EIP
Epoch Investment Partners
New York
|
+$75.2M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$61.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$439M |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$280M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$259M |
| 4 |
BlackRock
New York
|
-$202M |
| 5 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$200M |
AZN Hedge Fund Activity: Q2 2023 in Review
1,091 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2023, worth a combined $35.3B — up 0.96% from $35B a quarter earlier.
Buyers outnumbered sellers: 112 funds opened new AZN positions and 67 closed out — a net gain of 45 holders — while 337 added to existing stakes and 386 trimmed.
The largest buyer was Jennison Associates, adding an estimated $413M. The largest seller was T. Rowe Price Associates, cutting an estimated $439M.
- 1,091 institutional investors held AstraZeneca (AZN) as of Q2 2023, up from 1,055 in Q1 2023.
- Funds reported $35.3B of AstraZeneca stock for Q2 2023, up 0.96% quarter-over-quarter.
- 112 funds opened new AstraZeneca positions in Q2 2023 and 67 closed out, a net change of +45 holders.
- The largest AstraZeneca buyer in Q2 2023 was Jennison Associates, an estimated $413M added.
- The largest AstraZeneca seller in Q2 2023 was T. Rowe Price Associates, an estimated $439M sold.
Based on aggregated 13F filings for Q2 2023.